SEED Therapeutics, a BeyondSpring (BYSI) subsidiary, announced that it has appointed Jackson Tai to its Board of Directors. Tai has most recently retired, or will soon retire, as a Non-Executive Director of Eli Lilly (LLY). He brings almost 50 years’ experience in finance, strategy, and risk governance to the SEED Therapeutics Board.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on BYSI: